PENG and LFCN Block Versus Lumbar Plexus Block for Postoperative Analgesia After Total Hip Arthroplasty

October 18, 2023 updated by: Hassan Mokhtar Elshorbagy Hetta, Minia University

Efficacy and Safety of Ultrasound Guided Combined Pericapsular Nerve Group Block and Lateral Femoral Cutaneous Nerve Versus Lumbar Plexus Block for Postoperative Analgesia After Total Hip Arthroplasty: Randomized Clinical Study.

Regional anesthesia for postoperative analgesia in THA includes epidural anesthesia and peripheral nerve blocks. However epidural anesthesia has a great role in THA, it has become restricted as perioperative antithrombotic drugs are generally used for orthopedic patients.

the study aim to evaluate and compare efficacy and safety of pericapsular nerve group block (PENG) block and lateral femoral cutaneous nerve versus Lumbar plexus block on postoperative analgesia in hip surgery.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

66

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Egypt
    • Minia
      • Minya, Minia, Egypt, 61511
        • Recruiting
        • Minia University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

(ASA) physical status I to III scheduled for hip surgery aged (30-70) years

Exclusion Criteria:

  • Drug allergy,
  • Morbid obesity (BMI >40 kg/m2),
  • Coagulopathy,
  • Psychiatric disorder,
  • Opioid dependence,
  • Patient refusal to give informed consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PENG and LFCN
Procedure: pericapsular nerve group and lateral femoral cutaneous nerve block
Will undergo pericapsular nerve group block (PENG) combined with lateral femoral cutaneous nerve under ultrasound guided block with 20 mL of 0.25% bupivacaine.
Experimental: lumbar plexus
Procedure: lumbar plexus block
Will undergo Lumbar plexus block (LPB) under ultrasound guided block with 20 mL of 0.25 % bupivacaine.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Visual analogue scale pain scores
Time Frame: 24 hour
pain score from 0-10 which 0 mean no pain and 10 the worst pain
24 hour

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
first analgesic request
Time Frame: 24 hour
time to demand nalbuphine
24 hour
total analgesic consumption
Time Frame: 24 hour
total nalbuphine in mg consumed in the first day
24 hour
First time to ambulate
Time Frame: 24 hours
first time to move
24 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Minia University

Investigators

  • Principal Investigator: hassan m. hetta, lecturer, minia university/ faculty of medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2023

Primary Completion (Estimated)

January 1, 2024

Study Completion (Estimated)

February 1, 2024

Study Registration Dates

First Submitted

December 7, 2022

First Submitted That Met QC Criteria

December 7, 2022

First Posted (Actual)

December 15, 2022

Study Record Updates

Last Update Posted (Actual)

October 19, 2023

Last Update Submitted That Met QC Criteria

October 18, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 473:10/2022

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe